Manufacturer profile
Biogen Inc.
Pharmaceutical company4 products tracked
4
products tracked
212,185
total reports
1
recalls on record
40.8%
serious overall
Products
showing 4 of 4
| Product | Approved | Reports ↓ | Top signal | Recalls |
|---|---|---|---|---|
| 2004 | 180,199 | General symptom | 0 | |
| 2014 | 12,956 | Drug delivery system malfunction | 0 | |
| 2019 | 11,525 | Multiple sclerosis | 1 | |
| 2016 | 7,505 | Post lumbar puncture syndrome | 0 |
Recall history · 1 on record
| Date | Class | Reason | Firm |
|---|---|---|---|
| Dec 9, 2020 | II | Failed dissolution specifications: out-of-specification test results observed during the buffer stage dissolution testing. | Biogen MA Inc. |
Class I = reasonable probability of serious harm · Class II = temporary or reversible · Class III = unlikely to cause harm.
Registration status
Some products from Biogen Inc. are not FDA-registered for human use. For unregistered substances (peptides, SARMs without human registration), no legitimate human-use supplier exists. The absence of a sourcing route is the safety information.